Lactobacillus helveticus Rosell®-52Updated 2 days ago
What is Lactobacillus helveticus Rosell®‑52—and why is it in Biotic⁺?
Rosell®‑52 is a trademarked probiotic strain with a strong safety and efficacy profile. It’s taxonomically verified, QPS-approved by EFSA, and has been used safely since at 2006.
🤔 What benefits does Rosell®‑52 provide?
Clinical and lab research shows it:
Survives stomach acid and bile, with ~50% viability after 2 hours at low pH—so it reaches your gut alive
Supports gut barrier integrity, protecting epithelial cell junctions and enhancing mucus production (Sherman et al., 2005)
Inhibits pathogens like E. coli, Campylobacter, Salmonella, and H. pylori in lab models (Johnson-Henry., et al 2005)
🤔 Why this specific (trademarked) strain?
Strain-verified & well-researched—Rosell®‑52 exists in cultures like CNCM/Pasteur and has a whole-genome sequence
QPS-approved and globally recognised, appearing on EFSA, FDA, Health Canada, TGA and other regulatory lists
Stable and practical—lactose-free and acid resistant
👤 How it works inside your body
Survives digestion — stays viable through stomach acid and bile
Adheres to gut lining — supports mucus and tight junction integrity
Blocks harmful microbes — inhibits pathogens like E. coli and H. pylori in the gut
Supports digestive and immune health, with evidence from both pediatric and adult studies in combination formulations
🤔 Why it’s included in Biotic⁺
Rosell®‑52 adds evidence-based support for gut barrier integrity, pathogen resistance, and digestive comfort. It’s a highly trusted, trademarked strain with decades of safe, robust use—perfectly matched to our mission of delivering consistent, science-backed benefits.
📚 References
Sherman PM. et al. (2005) Probiotics reduce enterohemorrhagic Escherichia coli 0157:H7- and enteropathogenic E. coli 0127:H6- induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infection and Immunity. 73 (8):5183-5188
Johnson-Henry. et al. (2005) Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. Journal of Infectious Disease. 191:2106-2117